Skip to main content

Table 2 Correlation of the expression of the two candidate miRNA and clinical features of SLE

From: NovelmiRNA-25 inhibits AMPD2 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus and represents a promising novel biomarker

Clinical characteristics N NovelmiRNA-25 P all-hsa-miR-1273h-5p P
Leukocyte
 < 3.5 2 0.39 ± 0.12 0.045 1.50 ± 0.67 0.452
 3.5–9.5 16 5.80 ± 5.38 2.78 ± 2.00
 > 9.5 3 0.64 ± 0.25 1.89 ± 1.02
Neutrophil
 1.8–6.3 15 6.06 ± 5.48 0.002 2.91 ± 2.01 0.271
 > 6.3 4 0.78 ± 0.34 1.72 ± 0.90
Albumin
 < 40 14 4.89 ± 4.85 0.034 2.98 ± 1.98 0.748
 40–55 1 16.81 3.65
C3
 < 0.79 15 5.67 ± 5.74 0.019 2.86 ± 2.04 0.173
 0.79–1.52 7 1.55 ± 1.61 1.73 ± 0.72
C4
 < 0.16 17 4.68 ± 5.76 0.524 1.75 (1.15, 2.57) 0.031
 0.16–0.38 4 2.74 ± 2.12 3.91 (2.45, 6.17)
Lupus anticoagulant
 0.75–1.25 10 3.65 ± 5.57 0.561 2.11 ± 1.24 0.034
 > 1.25 3 5.62 ± 4.57 4.58 ± 2.50
24 h urine protein
 < 0.5 3 8.65 ± 8.17 0.074 4.36 ± 2.80 0.073
 > 0.5 9 2.80 ± 2.73 2.11 ± 1.25
Alanine aminotransferase
 7–40 14 5.36 ± 5.96 0.984 2.79 ± 1.98 0.61
 > 40 2 5.45 ± 0.03 3.57 ± 1.96
Anti-ds-DNA antibody
 Positive 12 1.99 (0.53, 6.59) 0.75 1.64 (1.07, 4.62) 0.553
 Negative 6 2.10 (0.73, 11.75) 1.64 (1.07, 4.62)
  1. C3/C4 complement 3/complement 4